Antiviral update. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Antiviral update. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

PI Perspect. 1997 Mar;(No 21):8-10. Unique Identifier : AIDSLINE AIDS/97702496

Abstract: Reports from the 1997 Fourth Conference on Human Retroviruses and Opportunistic Infections continued to present the success of three-drug combinations for the treatment of HIV, and some studies indicate enough restoration of the immune system to sufficiently overcome some opportunistic infections. Updates are provided on previously-reported studies as well as those involving new drugs and combinations, including therapies for advanced disease. Results indicate that 3TC should only be used as part of a three-drug combination. Other reports show that people who start protease inhibitor therapy with low CD4+ cell counts (fewer than 100 cells) and get good CD4+ cell responses are still at risk of developing opportunistic infections, but it is advised that they should continue to take their prophylaxis therapies. Finally, preliminary results indicate that the new generation of nucleoside analogues, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors offer a significant advantage over the current generation of drugs. This will allow new therapies and new combination options for people who have already used or are intolerant to the currently available therapies.

Keywords: Anti-HIV Agents/ADMINISTRATION & DOSAGE/CHEMICAL SYNTHESIS/ *THERAPEUTIC USE CD4 Lymphocyte Count Drug Design Drug Therapy, Combination HIV Infections/*DRUG THERAPY HIV Protease Inhibitors/ADMINISTRATION & DOSAGE/CHEMICAL SYNTHESIS/THERAPEUTIC USE Human Reverse Transcriptase Inhibitors/ADMINISTRATION & DOSAGE/CHEMICAL SYNTHESIS/THERAPEUTIC USE Viral Load NEWSLETTER ARTICLE
970830
M9781253

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .